Abstract 15962: Age, Sex, and Race Differences in Statin Discontinuation and Side Effect Patterns. The REasons for Geographic And Racial Differences in Stroke (REGARDS) Study
Introduction: Many people discontinue statin therapy, with side effects thought to be a common reason for discontinuation. Determining the frequency of, and the reasons for, statin discontinuation can provide insight on how to increase statin adherence.
Methods: We analyzed data from 9,025 REGARDS participants who completed a study visit and a questionnaire on statin use and side effects in 2014-2016. The REGARDS study is a nationwide population-based cohort of US blacks and whites ≥45 years of age. Covariates in the multivariable analyses included sociodemographics, cigarette smoking, diabetes, history of cardiovascular disease, blood pressure, and chronic kidney disease.
Results: Statin discontinuation was more common among participants <65 years of age and women, and no differences were present by race (Table). After multivariable adjustment, prevalence ratios for statin discontinuation for participants ≥65 vs. <65 years of age, women vs. men, and whites vs. blacks were 0.80 (95%CI 0.69-0.93), 1.54 (95%CI 1.37-1.74) and 0.93 (0.83-1.05), respectively. Among participants who discontinued statins, those ≥65 years of age, men, and whites were more likely to have done so with a doctor’s advice. Side effects were the most common reason for discontinuation, particularly for those ≥65 years of age, women and whites. Cost was a more common reason for statin discontinuation for participants <65 years of age. After multivariable adjustment, participants ≥65 vs. <65 years of age, women vs. men, and whites vs. blacks were more likely to report side effects as the reason for discontinuation (prevalence ratios 1.20 [95%CI 1.03-1.41], 1.17 [95%CI 1.05-1.30] and 1.27 [95%CI 1.12-1.43], respectively).
Conclusions: Statin discontinuation and the occurrence of side effects among those who discontinue statins differ by age, sex and race. Interventions to reduce statin discontinuation may require distinct strategies for specific age, sex and race subgroups.
Author Disclosures: L.D. Colantonio: None. R.M. Tanner: None. K.L. Monda: Employment; Significant; Amgen, Inc. R. Dent: Employment; Significant; Amgen, Inc. M.E. Farkouh: Research Grant; Significant; Amgen, Inc. B. Taylor: Employment; Significant; Amgen, Inc. R.S. Rosenson: Research Grant; Significant; Amgen, AstraZeneca, Catabasis, Medicines Company, Sanofi. Honoraria; Modest; Kowa. Consultant/Advisory Board; Modest; Amgen, Akcea, AstraZeneca, CVS Caremark, Eli Lilly, GSK, Sanofi. P. Muntner: Research Grant; Significant; Amgen. Consultant/Advisory Board; Modest; Amgen. M.M. Safford: Research Grant; Significant; Amgen Inc. Consultant/Advisory Board; Significant; diaDexus.
- © 2016 by American Heart Association, Inc.